Intralipid Related Effect on NKcells in Patients With Unexplained Recurrent Spontaneous Abortion

Overview

Evaluating the effect of intralipid on the natural killer cells

Full Title of Study: “Intralipid Related Effect on NKcells in Patients With Unexplained Recurrent Spontaneous Abortions”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 20, 2018

Detailed Description

This study will done on women with recurrent spontaneous abortions having increased NKCELLS activity and evaluate the effect of Intralipid on them after re-estimation of NKcells activity again after one week of Intralipid adminstration

Interventions

  • Drug: Intralipid
    • Adose of intralipid given and rechecking NKcells activity

Arms, Groups and Cohorts

  • Experimental: One armed
    • One group of patient will take Intralipid for all

Clinical Trial Outcome Measures

Primary Measures

  • Change in NK cells activity after injection of intralipid
    • Time Frame: One week
    • NK cells is measured before and after injection of intralipid and is noticed for change in activity

Participating in This Clinical Trial

Inclusion Criteria

  • All women icluded having recurrent spontaneous abortions equal or more than twice.
  • Alittle women having increased NKCELLS activity.

Exclusion Criteria

  • Any other diseases causing miscarriage as autoimmune (lupus erythematosus or antiphospholipid antibodies syndrome )or endocrinopathy (diabetes mellitus, thyroid disorders and hyperprolactinaemia)or thrombophilia (factor v leiden mutation, protein c or s deficiency, prothrombin G20210A mutation, antithrombin III deficiency ) or abnormal karyotyping to one or both of parents or previous history of hormonal contraception or intrauterine device usage at last 3 months or any contraindications for intralipid usage.

Gender Eligibility: Female

Women with recurrent spontaneous abortions

Minimum Age: 18 Years

Maximum Age: 38 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Ahmed Mohamed Bahaa Eldin Ahmed
  • Collaborator
    • Ain Shams Maternity Hospital
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Ahmed Mohamed Bahaa Eldin Ahmed, Clinical professor – Ain Shams Maternity Hospital
  • Overall Official(s)
    • Hassan T Khairy, Professor, Study Director, Hassan Tawfik office
  • Overall Contact(s)
    • Sobhy R Mohammed, MBBCH, 01003815460, Garavandya@hotmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.